CEO: | Mark Crossley |
CFO & Executive Director: | Ryan Preblick |
Chairman: | Graham Hetherington |
Independent Non-Executive Director: | Barbara Ryan |
Independent Non-Executive Director: | Jo Le Couilliard |
Independent Non-Executive Director: | Keith Humphreys |
Independent Non-Executive Director: | Mark Stejbach |
Independent Non-Executive Director: | David E. Wheadon |
Independent Non-Executive Director: | Peter Bains |
Senior Independent Director: | Juliet Thompson |
Non-Executive Dir: | Jerome Lande |
Address: | 234 Bath Road, Slough, Berkshire, United Kingdom, SL1 4EE |
Website: | http://www.Indivior.com |
Sector: | Pharma and Biotech(LSE) |
Index: | FTSE 250, FTSE 350, FTSE All-Share |
Overseas Listings: | BATSLON:INDVL |
ISIN: | GB00BN4HT335 |
Currency | UK Pounds |
Share Price | 837.00p |
Change Today | 0.000p |
% Change | 0.00 % |
52 Week High | 1,764.00 |
52 Week Low | 576.50 |
Volume | 0 |
Shares Issued | 126.53m |
Market Cap | £1,059.03m |
Beta | 1.53 |
RiskGrade | 314 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 2 |
Buy | 2 |
Neutral | 0 |
Sell | 0 |
Strong Sell | 0 |
Total | 4 |
No dividends found |
CEO | Mark Crossley |
Chair | Graham Hetherington |
You are here: research